James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $549.29, for a total value of $5,492,900.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,368,398.04. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total value of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.87, for a total value of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.

United Therapeutics Stock Up 0.1%

Shares of United Therapeutics stock traded up $0.56 on Friday, hitting $545.96. 451,821 shares of the company were exchanged, compared to its average volume of 479,317. The stock has a market capitalization of $23.18 billion, a price-to-earnings ratio of 20.15, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The company has a 50-day moving average price of $567.24 and a 200 day moving average price of $521.17. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $6.63 earnings per share. Research analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Raymond James Financial initiated coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright raised their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada reduced their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Torren Management LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $26,000. Activest Wealth Management boosted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $31,000. International Assets Investment Management LLC boosted its position in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.